Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen

JA Sparano, Wiernik Ph, Margery Strack, +3

Blood

Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

RS Finn, Carmelo Bengala, Nuhad Ibrahim, +6

Cancer Research

Breast OncologyCancer ManagementPathologyOncologyMetronomic Therapy +15

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer

Lori J. Goldstein, Anne O’Neill, JA Sparano, +4

Journal of Clinical Oncology

Breast OncologyNegative Breast CancerPathologyGynecologyPharmacotherapy +20

Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: Phase II study CA180088

E. Mayer, Jean‐François Baurain, JA Sparano, +6

Journal of Clinical Oncology

Advanced Her2/neuBreast OncologyEr/pr-positive Breast CancerMedicinePharmacology +10

A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer.

Edith A. Perez, Xavier Pivot, Eduard Vrdoljak, +5

Cancer Research

Ixa-induced PnNeuropathic PainPharmacotherapyPeripheral NervesPre-clinical Pharmacology +18

Survival After Phase II Treatment of Advanced Renal Cell Carcinoma with Taxol or High-Dose Interleukin-2

Euan Walpole, J. P. Dutcher, JA Sparano, +8

Journal of Immunotherapy

Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Sylvia Adams, Ronan Gray, Sandra Demaria, +8

Cancer Research

Breast OncologyImmunologyPathologyImmunotherapyDfs Events +15

Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials.

Henri Roché, R Li, J. Ro, +7

Cancer Research

Breast OncologyMbc ResistantCancer ManagementPharmacotherapyDrug Resistance +16

Phase I-II study of the histone deacetylase inhibitor (HDACi) vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer (MBC): New York Cancer Consortium trial P7703.

B Ramaswamy, Kapil N. Bhalla, Brian E. Cohen, +10

Cancer Research

Metastatic Breast CancerOncologyBreast OncologyHistone Deacetylase InhibitorMedicine +11

Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.

K. Kalinsky, JA Sparano, Min‐Soo Kim, +8

Journal of Clinical Oncology